Table 1.

Univariate Cox proportional hazards models for BRFS

	Training cohort		Validation cohort
Variable	HR (95% CI)	P *	HR (95% CI)	P *
Age
1-unit increase (continuous)	1 (0.97 to 1.02)	.92	1.05 (1.00 to 1.10)	.07
PSA
1-unit increase (continuous)	1.041 (1.02 to 1.06)	<.001	1.023 (0.97 to 1.08)	.43
ERG status
Fusion vs no fusion	0.89 (0.63 to 1.25)	.49	1.20 (0.66 to 2.19)	.55
Grade groups (GG)
GG2 vs GG1	1.56 (1.01 to 2.42)	.046	3.29 (1.39 to 7.80)	.007
≥GG3 vs GG1	2.63 (1.73 to 3.99)	<.001	4.73 (1.72 to 13.03)	.003
pStage
T3a vs T2	2.38(1.57 to 3.62)	<.001	2.97 (1.65 to 5.34)	<.001
T3b vs T2	5.04 (3.38 to 7.51)	<.001	6.23 (2.58 to 15.04)	<.001
Extraprostatic extension
Yes vs no	3.20 (2.30 to 4.47)	<.001	3.42 (1.99 to 5.86)	<.001
Seminal vesicle invasion
Yes vs no	4.38 (2.79 to 6.88)	<.001	4.66 (1.99 to 10.94)	<.001
Surgical margin
Yes vs no	2.95 (2.11 to 4.12)	<.001	3.17 (1.72 to 5.86)	<.001
PTEN status
Loss vs intact	1.92 (1.35 to 2.73)	<.001	2.67 (1.55 to 4.62)	<.001
PTEN loss (% cores)
Low (1%–50%) vs intact (0%)	1.61 (1.00 to 2.60)	.05	1.53 (0.64 to 4.67)	.34
High (>50%) vs intact (0%)	2.24 (1.46 to 3.44)	<.001	3.71 (2.02 to 6.79)	<.001
PTEN loss (% cells)
Low (1%–65%) vs intact (0%)	1.47 (0.89 to 2.41)	.13	1.82 (0.91 to 3.64)	.09
High (>65%) vs intact (0%)	2.39 (1.57 to 3.62)	<.001	4.95 (2.48 to 9.90)	<.001

^*Two-sided log-rank test. BRFS = biochemical recurrence-free survival; CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen; pStage = pathological stage; PTEN = phosphatase and tensin homolog.